The Brucella abortus type IV secretion system (T4SS), encoded by the virB genes, is essential for survival in mononuclear phagocytes in vitro. In the mouse model, a B. abortus virB mutant was initially able to colonize the spleen at the level of the wild type for approximately 3 to 5 days, which coincided with the development of adaptive immunity. To investigate the relationship between survival in macrophages cultivated in vitro and persistence in tissues in vivo, we tested the ability of mutant mice lacking components of adaptive immunity to eliminate the virB mutant from the spleen during a mixed infection with the B. abortus wild type. Ifng ؊/؊ or ␤ 2 m ؊/؊ mice were able to clear the virB mutant to the same degree as control mice. However, spleens of Rag1 ؊/؊ mice and Igh6 ؊/؊ mice were more highly colonized by the virB mutant than control mice after 14 to 21 days, suggesting that, in these mice, there is not an absolute requirement for the T4SS to mediate persistence of B. abortus in the spleen. Macrophages isolated from Igh6 ؊/؊ mice killed the virB mutant to the same extent as macrophages from control mice, showing that the reduced ability of these mice to clear the virB mutant from the spleen does not correlate with diminished macrophage function in vitro. These results show that in the murine model host, the T4SS is required for persistence beyond 3 to 5 days after infection and suggest that the T4SS may contribute to evasion of adaptive immune mechanisms by B. abortus.
Brucella abortus is one of the causative agents of brucellosis, a chronic zoonotic infection characterized by bacterial persistence in the reticuloendothelial system (RES) of the liver, spleen, and lymph nodes. The chronic infection of the RES observed during human brucellosis can be studied in the murine model host. A signature-tagged transposon screen identified a type IV secretion system (T4SS) as an essential virulence factor for persistence in the murine RES (11) . The T4SS is encoded by the virB locus on chromosome II of the B. abortus genome. Mutational inactivation of the T4SS reduces the ability of B. abortus to survive and/or replicate in human epithelial cell lines (HeLa cells), murine bone marrow-derived macrophages, and macrophage-like cell lines (3, 5, 8, 14, 29, 30) , and similar phenotypes have been described for Brucella melitensis and Brucella suis virB mutants (7, 10, 16, 24) . Within murine bone marrow-derived macrophages, B. abortus traffics to an endoplasmic reticulum (ER)-like compartment, where it localizes to ER exit sites. In contrast, virB mutants fail to acquire ER markers (3, 4) . These differences in cellular trafficking are reflected in the kinetics of bacterial growth and/or killing: whereas wild-type (wt) B. abortus is able to replicate in macrophages in vitro, virB mutant bacteria are eliminated within the first 24 h after infection (3, 29, 30) .
These observations raise the question whether the T4SS is required for evasion of macrophage killing mechanisms in vivo. The role of the T4SS in evading two major macrophage killing mechanisms was recently addressed by comparing the ability of mice defective for production of reactive nitrogen intermediates (Nos2 Ϫ/Ϫ mice) and reactive oxygen intermediates (gp91phox Ϫ/Ϫ mice) with their congenic wild-type mice to check growth of B. abortus and an isogenic virB mutant in the RES. This study showed that neither the inducible nitric oxide synthase nor NADPH oxidase was responsible for the severe in vivo growth defect of the virB mutant (30) .
Since B. abortus virB mutants are 100-fold attenuated for intracellular growth within only 5 to 8 h of in vitro infection of macrophages, it seems reasonable to expect that, if bacteria entered macrophages at the onset of infection, then attenuation in vivo should manifest early during infection of mice as well. However, a recent screen of 672 Brucella melitensis signature-tagged transposon mutants for genes required for colonization of murine spleens 5 days after infection did not identify any transposon insertions in the virB locus (18) . This result was somewhat puzzling, since screening of a smaller B. abortus signature-tagged mutant bank (178 mutants) in mice identified two insertions in the virB locus (11) . One major difference in the design of the latter screen was the recovery of mutants from the spleen at 2 weeks and 8 weeks after infection. A possible interpretation of these in vivo data is that, unlike during in vitro growth in host cells, the T4SS is only required for bacterial growth in the RES at late times (Ͼ5 days) after infection. In order to address this question experimentally, we studied the kinetics of infection of a virB mutant in both wildtype and mutant mouse strains.
MATERIALS AND METHODS
Bacterial strains, media, and culture conditions. Bacterial strains used were Brucella abortus 2308 and its isogenic mutant, BA41 (11) , which has an insertion of mTn5Km2 at nucleotide 1232 of the B. abortus virB locus (GenBank accession number AF226278). This insertion is located 59 bp downstream of the virB1 gene and is polar on the expression of downstream genes in the virB operon (31) . Strains were cultured on tryptic soy agar (TSA; Difco/Becton-Dickinson, Sparks, MD) or in tryptic soy broth at 37°C on a rotary shaker. Bacterial inocula for infection of mice were cultured on TSA plus 5% blood (1) . For cultures of strain BA41, kanamycin (Km) was added to the culture medium at 100 mg/liter. All work with live B. abortus was performed at biosafety level 3.
Infection of mice. C57BL/6, B6.129S7-Rag1 tm1Mom (21) mice carrying a targeted knockout of the gene encoding recombination activating gene 1, B6.129S2-Cd4 tm1Cgn (27) mice carrying a targeted knockout of the gene encoding CD4, B6.129S2, Igh-6 tm1Mak (15) mice carrying a targeted knockout of the gene encoding immunoglobulin Mu chain, and B6.129S7-Ifng tm1Ts /J (6) mice carrying a targeted knockout of the gene encoding interferon gamma (IFN-␥) were obtained from the Jackson Laboratory (Bar Harbor, ME). B6 and B6.129-B2m tm1Jae N12 (33) mice carrying a targeted knockout of the gene encoding ␤ 2 -microglobulin were obtained from Taconic Farms (Germantown, NY). Mice were held in microisolator cages with sterile bedding and water and irradiated feed in a biosafety level 3 facility. For infection experiments, groups of five knockout mice and five age-matched controls per time point were inoculated intraperitoneally (i.p.) with 0.1 ml of phosphate-buffered saline (PBS) containing 5 ϫ 10 5 to 10 ϫ 10 5 CFU of B. abortus. At the appropriate time points, mice were euthanized by CO 2 asphyxiation, and the spleens were collected aseptically at necropsy. The spleens were homogenized in 3 ml of PBS, and serial dilutions of the homogenate were plated on TSA and TSA plus Km for enumeration of CFU. For mixed infection experiments, the log ratio was calculated as the geometric mean of CFU mutant/CFU wild type recovered from spleens. Experimental groups each contained five knockout mice and five age-matched controls from the same supplier, aged 6 to 10 weeks. All animal experiments were approved by the Texas A&M University Laboratory Animal Care and Use Committee or the UC Davis Institutional Animal Care and Use Committee and were conducted in accordance with institutional guidelines.
Confirmation of mutant mouse phenotypes. Flow cytometry analysis was used to confirm mutant phenotypes of ␤ 2 m Ϫ/Ϫ , Cd4 Ϫ/Ϫ , and Igh6 Ϫ/Ϫ mice. Spleens from infected mice were homogenized in 3 ml PBS, and serial dilutions were plated on TSA or TSA plus Km to enumerate CFU. The remaining cells were labeled for analysis by flow cytometry. Briefly, after passing the cells through a 100-m cell strainer and treating the samples with ACK buffer (0.15 M NH 4 Cl, 1.0 mM KHCO 3 , 0.1 mM Na 2 EDTA, pH 7.2) to lyse red blood cells, the cells were washed with PBS (Gibco) containing 1% bovine serum albumin (PBS-BSA). Portions of the splenocytes were stained at 4°C with the appropriate monoclonal antibodies (MAb): either fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD8a (Ly-2) MAb, FITC-conjugated rat anti-mouse CD45R/B220 MAb (Pharmingen, San Diego, CA), or FITC-conjugated rat antimouse CD4 (L3T4) MAb. The cells were washed with PBS-BSA and fixed with 4% formaldehyde for 1 h. Finally, samples were washed as before and resuspended in PBS-BSA. Flow cytometry analysis was performed using a FACSCalibur (Becton Dickinson, San Diego, CA), and data were collected for 10,000 cells/ sample (data not shown). Mice that did not exhibit the expected phenotypes were eliminated from the data analysis.
Isolation of bone marrow-derived macrophages. Bone marrow-derived macrophages were isolated from C57BL/6, Igh6 Ϫ/Ϫ , and Cd4 Ϫ/Ϫ mice following standard protocols. Briefly, after aseptically obtaining femurs from the mice, the bone marrow cells were flushed out with 6 ml of cold RPMI medium 1690 (RPMI; Gibco, Rockville, MD). Cells were pelleted at 1,000 rpm for 10 min at 4°C. The cells were resuspended in BMM medium (RPMI supplemented with 20% heat-inactivated fetal bovine serum, L-cell conditioned medium, 1 mM glutamine, 1% nonessential amino acids, and 1% antibiotic-antimycotic [Gibco, Rockville, MD]) and placed in petri dishes at 37°C in 5% CO 2 . At day 3 cells were fed by adding 10 ml of BMM medium and incubated for an additional 5 days in the presence of CO 2 . At day 7, the bone marrow-derived macrophages were harvested by removing the medium and adding cold PBS. Macrophages were centrifuged at 1,000 rpm for 10 min at 4°C, resuspended in RPMIsup (RPMI supplemented with 20% heat-inactivated fetal bovine serum, 1 mM glutamine, and 1% nonessential amino acids), and counted for the infection assays.
Isolation of resident peritoneal macrophages. Resident peritoneal macrophages were isolated from C57BL/6, Igh6 Ϫ/Ϫ , and Cd4 Ϫ/Ϫ post mortem, following standard protocols. Briefly, peritoneal fluid was harvested after injecting the animal's abdomens with cold RPMI supplemented with heparin. After injection, the abdomen of the animal was massaged and the liquid was extracted from the peritoneal cavity. Fluids were centrifuged at 1,200 rpm for 10 min at 4°C, and the pellets were resuspended in RPMI supplemented with 20% heat-inactivated fetal bovine serum, 1 mM glutamine, 1% nonessential amino acids, and 1% antibioticantimycotic (Gibco, Rockville, MD) and placed in petri dishes at 37°C in 5% CO 2 . After incubation for 3 h at 37°C under 5% CO 2 , nonadherent cells were removed from the petri dishes by aspiration, and the adherent macrophages were rinsed twice with PBS, counted, and plated in 24-well plates with fresh medium without antibiotic-antimycotic for subsequent infection.
Splenic adherent cells. Splenic cells were isolated from C57BL/6 and Igh6
mice by homogenizing spleens in 3 ml of RPMI supplemented with 20% heatinactivated fetal bovine serum, 1 mM glutamine, 1% nonessential amino acids, and 1% antibiotic-antimycotic (Gibco, Rockville, MD). Cells were centrifuged at 1,000 rpm for 10 min at 4°C. The cells were resuspended in 10 ml of the above medium and placed in petri dishes at 37°C in 5% CO 2 overnight. The nonadherent cells were removed from the petri dishes by aspiration, and the adherent cells were rinsed twice with PBS, counted, and plated in 24-well plates with fresh medium without antibiotic-antimycotic for subsequent infection. Macrophage infection. For macrophage killing assays, 24-well microtiter plates were seeded with macrophages at a concentration of 2 ϫ10 5 cells/well in 0.5 ml of RPMIsup and incubated overnight at 37°C in 5% CO 2 . The inocula were prepared by growing with shaking in tryptic soy broth for 24 h and then subsequent dilution in RPMIsup to a concentration of 4 ϫ 10 7 CFU/ml. Approximately 2 ϫ 10 7 bacteria in 0.5 ml of RPMIsup, containing B. abortus 2308 (wild type) or its isogenic virB mutant, were added to each well of macrophages. Three independent assays were performed with triplicate samples, and each experiment included control (C57BL/6) macrophages together with either Igh6 Ϫ/Ϫ or Cd4 Ϫ/Ϫ macrophages. Microtiter plates were centrifuged at 250 ϫ g for 5 min at room temperature in order to synchronize infection. Cells were incubated for 20 min at 37°C in 5% CO 2 , and free bacteria were removed by three washes with PBS. RPMIsup plus 50 mg gentamicin per ml was added to the wells, and the cells were incubated at 37°C in 5% CO 2 . After 1 h, the RPMIsup plus 50 g/ml gentamicin was replaced with medium containing 25 g/ml gentamicin. Wells were sampled at time points between 1 and 48 h after infection by aspirating the medium, lysing the macrophages with 0.5 ml of 0.5% Tween 20, and rinsing each well with 0.5 ml of PBS. Viable bacteria were quantified by dilution in sterile PBS and plating on TSA and TSA plus Km. For macrophage infection with opsonized bacteria, Brucella abortus 2308 or the virB mutant was treated with a 1:4,000 dilution of naïve rabbit serum, anti-Brucella rabbit serum (Difco), or PBS (nonopsonized) for 1 h at 37°C, as described by Bellaire et al. (2) . This dilution of both naïve and immune sera was confirmed by microscopy to be nonagglutinating for Brucella abortus. After opsonization, inocula were prepared and bone marrow-derived macrophages infected as described above.
Statistical analysis. For determination of statistical significance between experimental groups at an individual time point, either a Student's t test or analysis of variance (ANOVA) was performed on the data after logarithmic conversion. A P value of Ͻ0.05 was considered significant.
RESULTS
Infection kinetics of the B. abortus wild type and virB mutant in mice. Determining the time point at which the virB mutant first begins to be eliminated from the spleen would give some insight into how the T4SS contributes to persistent infection by B. abortus. To this end, a mixed infection experiment was used to assess the level of colonization of both the wild type and the virB mutant in the same animals. In a previous study, the rate of clearance of BA41 (virB) from mouse spleens during mixed infection was found to be comparable to that observed when mice were inoculated individually with B. abortus BA41 (11) . The results of this study showed that by 14 days postinoculation, approximately 10-fold more wild-type than mutant bacteria were recovered from splenic tissue in either mixed or individual infections, thereby validating the use of mixed infection for our current study.
To determine when the virB mutant begins to be cleared from splenic tissue, we performed a kinetic study of infection of BA41 compared to its isogenic wild-type strain 2308 (Fig. 1) . To reproduce the experimental design of the original STM screens (11, 18) , BALB/c mice were used. An inoculum consisting of 5 ϫ 10 5 CFU containing a 1:1 mixture of B. abortus 2308, and BA41 (virB) was administered i.p. to the mice.
Groups of five mice were sacrificed at the time points indicated for determination of splenic CFU. The results of this experiment showed that the CFU of the virB mutant recovered from the spleens was nearly identical to that of the wild type at 3 days postinfection (Fig. 1A) . The mean log ratio of wild type to virB mutant in each mouse was also not significantly different from 1.0 until day 7 postinfection (Fig. 1B) , suggesting that the virB mutant is initially able to colonize the spleen at levels similar to the wild type.
Based on these results, we hypothesized that one possible explanation for the different observations obtained using in vivo and in vitro models could be that, in addition to its described effect on intracellular trafficking in macrophages, the T4SS may allow B. abortus to evade other components of immunity in vivo. To test this hypothesis, we screened a group of mutant mice to identify strains that allowed prolonged persistence of the virB mutant.
Since the clearance of the virB mutant from the spleens of the mice correlated with the development of adaptive immunity, we examined the ability of mice defective in components of adaptive immunity to eliminate the virB mutant. Many of these mutant mice are available on a C57BL/6 strain background but not on a BALB/c background. C57BL/6 mice have been described as more resistant to B. abortus infection than BALB/c mice (22) ; therefore, we repeated the initial experiment using C57BL/6 mice to determine whether the clearance of the virB mutant proceeded with similar kinetics in this mouse strain. In this experiment, we included additional time points to determine more precisely when mice start to clear the virB mutant. The results ( Fig. 2A and B) showed that both the wild type and the virB mutant colonized C57BL/6 mice at similar levels during the first 24 h and that a significant difference (P Ͻ 0.05) between numbers of B. abortus 2308 and the virB mutant was first observed at 5 days postinfection. At days 14 and 21 postinfection, the recovery of the virB mutant was reduced by 2 (day 14) and 3 (day 21) orders of magnitude compared to the wild type. Thus, although the C57BL/6 mice cleared the virB mutant more rapidly between 7 and 21 days, the capacity of the virB mutant to colonize the spleen during the first few days of infection was similar in both mouse strains.
An IFN-␥ defect does not rescue the virB mutant. To learn how the T4SS mediates evasion of host immune mechanisms to initiate persistent infection, we first identified immune mechanisms required for clearance of the virB mutant from murine spleens. Toward this goal, knockout mice with specific defects in components of the immune response were used to identify mouse strains with a reduced ability to eliminate the virB mutant from the spleen. We hypothesized that identification of mouse mutations that can rescue the virB mutant, but do not permit increased replication of wild-type B. abortus, may pinpoint immune mechanisms that are circumvented by B. abortus using its T4SS.
One host response mechanism that has been shown to be elicited in mice by B. abortus infection during the time when numbers of the virB mutant start to decline is the production of IFN-␥ (9, 12). Since IFN-␥ production has been shown to be crucial for controlling B. abortus infection in mice (22, 32) , we postulated that the Ifng Ϫ/Ϫ mice, which are unable to produce IFN-␥ (6), might be deficient in controlling replication of the virB mutant. To test this idea, we performed a mixed infection study in Ifng Ϫ/Ϫ mice ( on October 1, 2017 by guest http://iai.asm.org/ (Fig. 3A) . Based on the infection kinetics determined in C57BL/6 mice, we chose 14-and 21-day time points for comparison of C57BL/6 and knockout mice, as the 2-and 3-log difference between CFU of the virB mutant and of the wild type recovered at these time points ( Fig. 2A and B) would enable us to detect significant differences between control and knockout mice without the use of large groups of experimental animals. If IFN-␥-activated macrophages controlled replication of the virB mutant in vivo, then we expected that the virB mutant would exhibit increased survival in the Ifng Ϫ/Ϫ mice. However, the virB mutant was recovered in lower numbers from the Ifng Ϫ/Ϫ mice than from C57BL/6 controls ( Fig. 3A and C) , suggesting that this is not the case. As has been observed previously (22) , wild-type B. abortus was recovered in significantly higher numbers from the spleens of Ifng Ϫ/Ϫ mice than C57BL/6 mice at both 14 (P ϭ 0.03) and 21 (P ϭ 0.01) days postinfection. At days 1 and 21 postinfection, we observed no significant difference between the ratios of wild-type B. abortus to virB mutant in Ifng Ϫ/Ϫ mice and the C57BL/6 controls ( Fig.  3B and D) . On day 14, the Ifng Ϫ/Ϫ mice actually showed increased clearance of the virB mutant compared to the C57BL/6 mice (P Ͻ 0.05). Based on these results, we concluded that the Ifng Ϫ/Ϫ mice do not have a specific defect in elimination of the virB mutant. Rag1 ؊/؊ mice permit increased splenic persistence of a B. abortus virB mutant. To determine whether complete inactivation of adaptive immunity rescues the virB mutant, we compared the ability of Rag1 Ϫ/Ϫ mice and the congenic C57BL/6 controls to clear the virB mutant after mixed infection.
Rag1
Ϫ/Ϫ mice are unable to generate functional B or T cells because of a defect in the recombinase-activating gene required for generating immunoglobulin and T-cell receptor molecules (21) . The results (Fig. 4A and C) of this experiment showed that both C57BL/6 mice and Rag1 Ϫ/Ϫ mice had lower bacterial loads of the virB mutant than wild-type B. abortus in the spleen at days 14 and 21. However, the ratio of BA41 (virB) to B. abortus 2308 (wild type) was higher in the Rag1 Ϫ/Ϫ mice than in the C57BL/6 controls ( Fig. 4B and D) . The spleens of Rag1 Ϫ/Ϫ mice contained a virB mutant/wt ratio of 1:22 in their spleens at day 21, whereas the C57BL/6 mice had a splenic virB mutant/wt ratio of 1:1,200, showing that Rag1 Ϫ/Ϫ mice were deficient at clearing the virB mutant ( Fig. 4B and D) . Thus, the Rag1 Ϫ/Ϫ mutation caused a partial rescue of the virB mutant in the mouse spleen without affecting recovery of wt B. abortus. (26) . We reasoned that in vivo, a defect in CD8 ϩ T-cell function might rescue the virB mutant. To test this idea, we performed mixed infections of C57BL/6 mice and mice deficient in ␤ 2 -microglobulin (␤ 2 m; a subunit of major histocompatibility complex [MHC] class I), which are unable to generate CD8 ϩ cytotoxic T cells due to an inability to synthesize functional MHC class I protein (33) . Figure 5A to D show that both the absolute numbers of the wild type and virB mutant and the ratio of virB mutant to wild-type B. abortus recovered from ␤ 2 m Ϫ/Ϫ mice were similar at days 1, 14, and 21 postinfection. These results show that abrogation of CD8 ϩ T-cell function in the ␤ 2 m Ϫ/Ϫ mice does not increase the persistence in the spleen of the virB mutant. These results suggested that the T4SS does not mediate evasion of CD8 ϩ T-cell-dependent immune functions.
To determine whether mice lacking CD4 ϩ T cells can rescue the B. abortus virB mutant, we performed a mixed infection study using Cd4 Ϫ/Ϫ mice ( Fig. 6A to D) . At day 1 postinfection, B. abortus 2308 and the virB mutant were recovered in equivalent numbers from both C57BL/6 mice and the Cd4 Ϫ/Ϫ mice, showing that the T4SS defect in the virB mutant does not affect initial colonization of either mouse strain. At day 14 postinfection, the Cd4 Ϫ/Ϫ mice had a higher ratio of virB mutant to wild type (1:5.7) in the spleens than did C57BL/6 mice (1:300). Further, at day 14 postinoculation, there were significantly more CFU of the virB mutant in the spleens of Cd4 Ϫ/Ϫ mice than in the spleens of C57BL/6 mice (P Ͻ 0.001). Remarkably, at day 21, the CFU of the virB mutant in spleens of Cd4 Ϫ/Ϫ mice were not significantly different from control mice, but CFU of the wild type were significantly lower (P ϭ 0.01) in spleens of the Cd4 Ϫ/Ϫ mice than in the spleens of C57BL/6 mice. Thus, the Cd4 Ϫ/Ϫ mice reduced CFU of the virB mutant by 1.5 orders of magnitude during the first 21 days postinfection, while control mice reduced CFU of the mutant by 3.5 orders of magnitude (Fig. 6A to D) .
The finding that the virB mutant was eliminated more slowly by the Cd4 Ϫ/Ϫ mice than by C57BL/6 mice during competitive infection prompted us to determine whether this was also the case if mice were inoculated individually with the wild type or virB mutant (Fig. 7) . As observed during mixed infections, the Cd4 Ϫ/Ϫ mice harbored fewer CFU of B. abortus 2308 in the spleen than C57BL/6 mice at 14 and 21 days after infection (Fig. 7A) . The virB mutant was recovered in similar numbers from C57BL/6 and Cd4 Ϫ/Ϫ mice at day 14, and at day 21 recovery of the mutant from Cd4 Ϫ/Ϫ mice was slightly higher than C57BL/6 mice; however, this difference was not significant (Fig. 7B) .
Both Rag1 Ϫ/Ϫ mice and Cd4 Ϫ/Ϫ mice are defective in B-cell function (21, 27) . The lack of functional B cells in these mice may therefore contribute to the reduced ability of these mice to clear the virB mutant. To determine whether mice lacking B cells can clear the B. abortus virB mutant from mice, we performed a mixed infection study using Igh6 Ϫ/Ϫ mice and control mice (Fig. 8A to D) . Igh6 Ϫ/Ϫ mice are deficient in immuno- mice had a virB mutant to wild type ratio of 1:1.3 in the spleen, while the ratio in C57BL/6 mice was 1:213. Further, the recovery of the virB mutant from spleens of Igh6 Ϫ/Ϫ mice at day 21 was significantly higher than the recovery from C57BL/6 mice (P Ͻ 0.01). A second experiment was performed, in which the wild type and virB mutant were administered individually to Igh6 Ϫ/Ϫ mice (Fig. 7) . The results of this experiment showed that the wild type was recovered from both Igh6 Ϫ/Ϫ and control mice in similar numbers at 14 days postinoculation; however, at day 21, the Igh6 Ϫ/Ϫ mice harbored lower levels of wild-type B. abortus in the spleen. The virB mutant was recovered in higher numbers than wild type at day 14 and day 21, but these differences were not significant. Taken together, the mixed and individual infection experiments revealed that the Igh6 Ϫ/Ϫ mice were slightly better at controlling replication of wild-type B. abortus but were more permissive for persistence of the virB mutant. Since the Igh6 Ϫ/Ϫ mice exhibited the most marked defect in clearing the virB mutant and no defect in clearing wt B. abortus, we chose this mouse strain for further characterization.
Macrophages isolated from Igh6 ؊/؊ mice do not differ from control macrophages in their ability to control replication of wild-type and virB mutant B. abortus. Since Igh6 Ϫ/Ϫ mice permitted persistence of the virB mutant for a longer duration than control mice, we next asked the question whether the Igh6 mutation could have pleiotropic effects that reduce the ability of macrophages from these mice to control intracellular replication. Although Igh6 Ϫ/Ϫ mice have been widely used to study B-cell-dependent responses to infection, no information is available on whether the Igh6 Ϫ/Ϫ mutation affects macrophage function. However, given the central role of the macrophage as a site for replication and as an effector cell controlling Brucella replication, we considered this possibility. To this end, we compared the ability of macrophages derived from Igh6 Ϫ/Ϫ knockout mice to limit intracellular replication of B. abortus 2308 or the virB mutant. For these experiments, a gentamicin protection assay was used to quantify replication of B. abortus in bone marrow-derived macrophages isolated from C57BL/6 mice and Igh6 Ϫ/Ϫ mice ( Fig. 9A and B) . Each experiment was performed in parallel with macrophages from control and knockout mice. These results showed that wild-type B. abortus decreased in numbers until 24 h after inoculation and then exhibited a net increase in CFU between 24 and 48 h. In contrast, the virB mutant declined below the limit of detection by 24 h and remained undetectable thereafter. Bone marrowderived macrophages isolated from C57BL/6 or Igh6 Ϫ/Ϫ mice did not differ in their ability to control replication of either wild-type B. abortus or the virB mutant.
Based on these results, we examined whether other macrophage populations, namely, adherent splenocytes and resident peritoneal macrophages isolated from C57BL/6 mice and Igh6 Ϫ/Ϫ mice, differed in their ability to limit replication of the virB mutant during the first 24 h after inoculation (Fig. 9C to  F) . In resident peritoneal macrophages from Igh6 Ϫ/Ϫ or control mice, wild-type B. abortus was present in similar numbers at 1 h and 24 h postinoculation (Fig. 9C) . In contrast, the virB mutant declined in numbers by 1 order of magnitude between 1 h and 24 h (Fig. 9D) . In adherent splenocytes, wild-type B. abortus exhibited a net increase in numbers between 1 and 24 h (Fig. 9E) , while CFU of the virB mutant decreased by approximately 1 order of magnitude (Fig. 9F) . No differences were observed between cells isolated from C57BL/6 or Igh6 Ϫ/Ϫ , and Cd4 Ϫ/Ϫ mice following inoculation with individual strains. Bars represent the geometric means Ϯ standard errors of data from groups of five mice, except where indicated by §, for which n ϭ 3. Statistical analysis between geometric means of the CFU of mutant and wild type recovered was performed using ANOVA. Asterisks denote significant differences (␣ ϭ 0.05) between CFU recovered from mutant mice compared to C57BL/6 mice.
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on October 1, 2017 by guest http://iai.asm.org/ that the Igh6 Ϫ/Ϫ mutation did not affect the ability of macrophages to take up or kill either wild-type B. abortus or the virB mutant after in vitro infection (Fig. 9A to D) . Similar results were obtained using bone marrow-derived or resident peritoneal macrophages isolated from Cd4 Ϫ/Ϫ mice (data not shown). These results show that the increased in vivo persistence of the virB mutant in Igh6 Ϫ/Ϫ mice does not correlate with an inherent defect in the ability of their macrophages to control intracellular replication of the virB mutant in vitro.
Killing of the B. abortus virB mutant by macrophages is not affected by the presence of Brucella-specific antibodies. One possible explanation for the increased persistence of the virB mutant in B-cell-deficient Igh6 Ϫ/Ϫ mice could be that uptake of opsonized B. abortus via Fc receptors may lead to increased killing of the virB mutant by macrophages, compared to wildtype B. abortus, which has been shown to survive within macrophages after opsonophagocytosis (2) . To test this possibility, we quantified the ability of bone marrow-derived macrophages to kill B. abortus 2308 or the virB mutant after opsonization with naïve or B. abortus-immune rabbit serum (Fig. 10 ). While opsonization with B. abortus-specific serum increased uptake of both wild-type and virB mutant B. abortus, resulting in 10-fold-greater bacterial numbers at 1 h postinfection, this difference was no longer evident at later time points: at 4, 8, 24, and 48 h, there was no significant difference between intracellular numbers of opsonized and nonopsonized bacteria.
DISCUSSION
The results of this study demonstrate that the B. abortus T4SS is not required for initial colonization of mice after i.p. inoculation but is required for persistence beyond 3 days postinfection. In light of results from previous studies, in which Brucella localized to phagocytic cells in the spleens of mice (13, 20, 23) , this result was surprising, because data obtained using infection of macrophages or macrophage cell lines cultivated in vitro showed a role for the T4SS in intracellular survival that was manifested as early as 4 to 8 h postinfection (Fig. 9) . Our findings are in accordance with those from Lestrate et al., who did not identify any virB mutants in two different screens for B. melitensis signature-tagged mutants attenuated at 5 days postinfection (18, 19) , as well as those of Rajashekara et al. (28) , who showed that a B. melitensis virB mutant was able to disseminate from the site of injection, suggesting that in B. melitensis the T4SS is also not essential for initial colonization of mice. The infection kinetics of the virB mutant in C57BL/6 mice (a decrease in numbers 3 to 5 days after mixed infection [ Fig. 2] ) correlate with the timing of adaptive immune responses, as Brucella-specific IgM antibodies first appear at 3 to 5 days after infection (data not shown). We therefore hypothesized that the T4SS allows B. abortus to evade an immune mechanism that is activated in the mouse after the first 3 days of infection.
To test this hypothesis, we screened a group of mutant (11), we recovered 100-to 1,000-fold-fewer CFU of the virB mutant from mice between 14 and 21 days compared to wild-type B. abortus, irrespective of whether a mixed inoculum was administered or whether the virB mutant and wild type were administered separately to mice. Based on this phenotype, we reasoned that the immune mechanism that selectively clears the virB mutant must be able to act on virB mutant bacteria but not on wild-type bacteria in the same animal. If mice lacked a component of immunity involved in clearing the virB mutant, then the virB mutant would be expected to be recovered in higher numbers than from control mice after mixed infection. The results of these experiments showed that inactivation of specific immune mechanisms in mice led to different effects on the ability of the virB mutant and wt to persist in the spleen ( Table 1 ), suggesting that different immune mechanisms may contribute to limiting persistence of wild-type B. abortus and strains lacking the T4SS. IFN-␥ production is elicited in B. abortus-infected mice and was shown to begin between 3 and 7 days postinfection (9), suggesting that in vivo, IFN-␥ might activate infected cells to kill the virB mutant selectively. However, our results (Fig. 3) show that the Ifng Ϫ/Ϫ mutation does not lead to a selective rescue of the virB mutant. These data are in agreement with our previous findings that clearance of virB mutants from mice is not dependent on inducible nitric oxide synthase or NADPH oxidase (30) , which are elicited by IFN-␥. Similarly, a ␤ 2 m Ϫ/Ϫ mutation affecting CD8 ϩ T-cell development also failed to rescue the virB mutant (Fig. 5) .
In contrast, a Rag1 Ϫ/Ϫ mutation increased the ability of the virB mutant to persist in the spleen (Fig. 4) . Since Rag1 Ϫ/Ϫ mice lack mature B and T cells, this result suggested that the T4SS may enable B. abortus to evade adaptive immunity mediated by these cell types. Rag1 Ϫ/Ϫ mice have been reported to be defective in controlling infection with B. melitensis (13) .
However, although the Rag1 Ϫ/Ϫ mice did not clear the virB mutant as well as C57BL/6 mice, at 14 and 21 days postinfection approximately 10-fold more of wild-type than virB mutant B. abortus was recovered from the spleens of the Rag1 Ϫ/Ϫ mice. Thus, the Rag1 Ϫ/Ϫ mice retained some ability to limit persistence of the virB mutant by mechanisms that do not depend on B and T cells.
Both Cd4 Ϫ/Ϫ and Igh6 Ϫ/Ϫ mice were less able to eliminate the virB mutant from the spleen than control mice after mixed infection (Fig. 6A to D and 8A to D) . These results suggested that B cells and/or CD4 ϩ T cells may be involved in clearance of the virB mutant. While it is tempting to speculate that the T4SS may enable B. abortus to evade immunity mediated by these cell types, an important consideration in the interpretation of these data is that the knockout mice used in this study may have additional defects or compensatory developmental changes in their immune systems that may affect their ability to clear the virB mutant. For example, CD4
ϩ T-cell help is required for antibody responses, and Cd4 Ϫ/Ϫ mice have been shown to generate an antibody response to a model antigen that was only 10% of that elicited in control mice (27) . Conversely, B cells have been shown to play a role in CD4
ϩ T helper cell function during murine malaria infection (17) . Therefore, additional approaches will be required to narrow down the exact defects in these knockout mice that permit prolonged colonization with B. abortus strains defective in the T4SS. It should be noted that Cd4 Ϫ/Ϫ mice were better able than control mice to control replication of wild-type B. abortus, which may be related to a lack of CD4 ϩ CD25 ϩ regulatory T cells in the mutant mice.
An Igh6 Ϫ/Ϫ mutation leading to an absence of B cells rescued the survival defect of the virB mutant. The decreased ability of Igh6 Ϫ/Ϫ mice to limit persistence of the virB mutant did not appear to be the result of a reduced capacity of their macrophages to control intracellular replication of the virB mutant, as bone marrow-derived, splenic, or resident peritoneal macrophages isolated from these mice were indistinguishable from control mice in their ability to limit intracellular growth of the virB mutant in vitro (Fig. 9) . Therefore, the inability of these mice to prevent persistence of the virB mutant appears to involve a defect that can only be modeled in vivo. The macrophage model has yielded important information on the function of the T4SS in the cell, namely, the subversion of intracellular trafficking to create the endoplasmic reticulumassociated replicative compartment (3, 4, 5) . Thus, this function is also expected to be important for T4SS-mediated survival of Brucella in vivo.
One possible interpretation of our results was that wild-type B. abortus and the virB mutant may differ in their ability to survive in macrophages after Fc receptor-mediated phagocytosis and that the absence of specific antibody in the Igh6 Ϫ/Ϫ mice could render them more permissive for growth of the virB mutant. Since it has been shown that B. abortus 2308 opsonized with immune serum can survive and replicate in human monocytes (2), we tested this possibility and showed that in vitro, opsonization with immune serum did not affect intracellular survival of the virB mutant.
An alternative interpretation of our data is that additional immune components, such as cytokines or cell populations other than macrophages, may function during infection to abortus strain persists at a higher level in mutant mice than in C57BL/6 mice; Ϫ, the B. abortus strain persists at a lower level in the mutant mouse strain than in C57BL/6; 0, no effect on the level of persistence.
b The virB mutant persisted at a higher level in mutant mice after mixed infection, but no significant difference was observed after individual infection.
c No effect on persistence of wild-type B. abortus was observed after mixed infection, but after individual infection of Igh6 Ϫ/Ϫ mice, spleens were colonized at a lower level 21 days postinfection. modulate the ability of macrophages to clear the virB mutant. The former idea is supported by the finding that human V␥9V␦2 T cells are able to limit intracellular growth of B. suis within autologous macrophages (25) . Thus, one function of the T4SS may be to interfere with recognition of infected macrophages by other immune cells. A second possibility is that the virB mutant B. abortus may persist in the spleens of Igh6 Ϫ/Ϫ and CD4 Ϫ/Ϫ mice within a cell population that has a reduced ability to kill the virB mutant, or that the virB mutant may be present extracellularly. Location of bacteria in a different cell population or in an extracellular location may also explain why the T4SS is not required for survival in the spleen during the first 3 days after infection. Additional experiments will be required to distinguish between these different possibilities and to define the role of the T4SS in immune evasion in vivo. We anticipate that the results will give us further insights into how the T4SS enables B. abortus to cause persistent infection.
